Compare PERF & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PERF | FHTX |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.6M | 173.4M |
| IPO Year | 2022 | 2020 |
| Metric | PERF | FHTX |
|---|---|---|
| Price | $1.92 | $1.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $2.98 | ★ $9.89 |
| AVG Volume (30 Days) | 176.0K | ★ 997.2K |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | $7.16 | N/A |
| Revenue Next Year | $10.42 | $15.98 |
| P/E Ratio | $26.42 | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $1.24 | $1.79 |
| 52 Week High | $2.15 | $7.61 |
| Indicator | PERF | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.49 | 12.33 |
| Support Level | $1.92 | N/A |
| Resistance Level | $1.95 | $5.35 |
| Average True Range (ATR) | 0.02 | 0.28 |
| MACD | -0.00 | -0.16 |
| Stochastic Oscillator | 43.80 | 6.51 |
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions. The company runs a hybrid business model of direct consumer business (B2C business) and enterprise business (B2B business). For B2C businesses, the company offers six mobile apps under the "YouCam" suite, along with one online editing service tool, YouCam Online Editor, featuring AI and AR technologies. For B2B businesses, the company offers AI and AR-powered solutions tailored for the beauty and fashion industry. Geographically, the company has a presence in the United States, Americas-other, France, Japan, and Others. The company generates the majority of its revenue from the United States.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.